{"url_path":"/sec/juns/8-k/2026-07-21/item-3-02","section_key":"item-3-02","section_title":"Item 3.02 Unregistered Sales of Equity Securities.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-21","source_url":"https://www.sec.gov/Archives/edgar/data/1679628/0001493152-26-034077-index.html","accession_number":"0001493152-26-034077","cik":"0001679628","ticker":"JUNS","issuer_name":"JUPITER NEUROSCIENCES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1679628/0001493152-26-034077-index.html","primary_entity_key":"0001679628","primary_entity_name":"JUPITER NEUROSCIENCES, INC."},"word_count":79,"has_tables":true,"body_markdown":"**Item\n3.02 Unregistered Sales of Equity Securities.**\n\n \n\nThe\ndisclosure set forth under Item 1.01 above is incorporated into this Item 3.02 by reference. The shares of the Company’s common\nstock issuable under the License Agreement are expected to be issued in reliance on the exemption from registration provided by Section\n4(a)(2) of the Securities Act of 1933, as amended, and/or Rule 506(b) of Regulation D promulgated thereunder, based in part on representations\nmade by PharmAla in the License Agreement."}